Hatem Soliman, MD, Assistant Member, Women’s Oncology and Experimental Therapeutics, Moffitt Cancer Center, suggests that administering eribulin (Halavan) in this scenario would be reasonable, because the patient is chemorefractory to taxane, anthracycline, and Xeloda. Also, tissue from the tumor should be analyzed by FoundationOne for molecular alterations, Soliman suggests.How would a community oncologist treat this patient? > >
CASE 2: HER2-Negative Chemotherapy-Resistant mBC
Kim W, 53-year-old postmenopausal woman of Asian decent from Morristown, New Jersey, who worked as an accountant.
2013: Presented to PCP after finding a lump in right breast. Referred to oncologist for standard diagnostic workup.
Diagnosed with infiltrating ductal adenocarcinoma; 5.5-cm lesion in lower outer quadrant of right breast and palpable ipsilateral axillary nodes, which were FNA+ for adenocarcinoma
Fluorescence in situ hybridization determined HER2-negative/ER+/PR+ tumor
Patient was able to work and carry out daily activities (KPS score 94)
Bone scan and chest diagnostic CT revealed no metastases
Neoadjuvant therapy begun with dose-dense AC: doxorubicin 60 mg/m2 IV q2 weeks followed by weekly paclitaxel 80 mg/m2 x 12
Patient underwent breast-conserving therapy (malignant cells in 7 axillary lymph nodes)
Surgery followed by chest wall and regional lymph node radiation therapy (5x/week for 6 weeks). Started nonsteroidal aromatase inhibitor.
5 months after adjuvant chemotherapy treatment, patient complained of bone pain.
Patient was unable to work, but could carry out self care and some home upkeep
Bone scan and CT scan revealed several metastases: 2 lesions on right leg bone measuring 2-3 cm, 2 lesions on liver measuring 2-3 cm; 1 lesion on lung measuring 2-3 cm
Patient identified as potentially resistant to taxane (having progressed within 12 months of last adjuvant therapy)
Liver biopsy and pathology showed metastases consistent with original breast cancer. Patient diagnosed with stage IV cancer
Histology confirmed HER2-negative/ER+/PR+ disease. Began therapy with denosumab for bone metastases
Also received Xeloda 1000 mg/m2 PO BID day 1-14
Also received Xeloda 1000 mg/m2 PO BID day 1-14
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More